Your browser doesn't support javascript.
Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021.
Lee, Eunju; Lee, Yeon-Kyeong; Kim, Tae Eun; Hwang, Insob; Jung, Yeon Haw; Lee, Hye Ryeon; Song, Jeongsuk; Park, Youngjoon; Cho, Enhi; Lee, Yeon-Kyeng.
  • Lee E; Adverse Event Management Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Lee YK; Adverse Event Management Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Kim TE; Adverse Event Management Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Hwang I; Adverse Event Management Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Jung YH; Adverse Event Investigation Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Lee HR; Adverse Event Investigation Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Song J; Adverse Event Management Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Park Y; Adverse Event Investigation Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Cho E; Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
  • Lee YK; Adverse Event Management Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju-si, South Korea.
Euro Surveill ; 26(33)2021 Aug.
Article in English | MEDLINE | ID: covidwho-1367740
ABSTRACT
The South Korea mass vaccination programme administered 3.8 million doses of COVID-19 vaccinations between 26 February and 30 April 2021. After 173 suspected anaphylaxis reports to the nationwide monitoring system for adverse events following immunisation, 44 anaphylaxis cases were confirmed using Brighton Collaboration case definitions. The rates per million doses were 18.2 cases and 6.2 cases for Vaxzevria and Comirnaty, respectively. Median time of onset was 14 min after vaccination and most cases had recovered at the time of review.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Anaphylaxis Type of study: Diagnostic study / Observational study Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.33.2100694

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Anaphylaxis Type of study: Diagnostic study / Observational study Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.33.2100694